AQST — Aquestive Therapeutics, Inc.

AQST Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenues: $12.8 million for Q3 2025, a 4% increase year-over-year (YoY) excluding prior year’s one-time deferred revenue recognition. Total revenues decreased from $13.5 million in Q3 2024 when including that deferred revenue.
• Manufacturer and Supply Revenue: Increased to $11.5 million from $10.7 million YoY, driven by higher revenues from Sympazan and Suboxone.
• Net Loss: $15.4 million ($0.14 per share) for Q3 2025, compared to a net loss of $11.5 million ($0.13 per share) in Q3 2024.
• Non-GAAP Adjusted EBITDA Loss: $8.6 million for Q3 2025, worsening from a loss of $6.6 million YoY.
• Cash Position: $129.1 million as of September 30, 2025.
• Full-Year Guidance: Revenue expected between $44 million and $50 million; non-GAAP adjusted EBITDA loss projected between $47 million and $51 million.

2. Strategic Updates and Business Highlights:

• Anaphylm Program: Positioned as the first oral medication for severe allergic reactions, with a PDUFA action date set for January 31, 2026. Prelaunch activities are underway, including marketing material preparation and hiring of district managers.
• Leadership Changes: Dr. Gary Slatko appointed as interim Chief Medical Officer to support Anaphylm, with Matthew Davis joining as Chief Development Officer to advance the Adrenaverse platform.
• International Expansion: Positive interactions with Health Canada and ongoing discussions with the European Medicines Agency (EMA) for Anaphylm applications, with filings expected in 2026.
• Base Business Performance: Stable demand from Indivior and growth in South America, particularly Brazil.

3. Forward Guidance and Outlook:

• Launch Readiness: Expecting to launch Anaphylm in Q1 2026 if FDA approval is granted. The company is well-financed to support this launch and ongoing operations through 2027.
• Adrenaverse Platform: Plans to resume development initiatives in 2026, including the AQST-108 program for alopecia areata, with a safety study expected to begin in January 2026.

4. Bad News, Challenges, or Points of Concern:

• Increased Losses: The net loss has widened compared to the previous year, raising concerns about the sustainability of operations without significant revenue growth.
• Competitive Pressures: A competitor has filed a citizens petition with the FDA, potentially impacting Anaphylm's approval timeline, although management remains confident in their position.
• Market Dynamics: The epinephrine market is heavily dominated by auto-injectors, with 95% of prescriptions in that category, posing a challenge for Anaphylm's market penetration.

5. Notable Q&A Insights:

• FDA Review Status: Management reported no negative impact from the FDA's recent leadership changes on their application review.
• Pricing Strategy: The company plans to price Anaphylm responsibly, focusing on patient access and working with payers to ensure coverage.
• Market Awareness: Strong interest and positive feedback from allergists regarding Anaphylm, with a focus on targeted marketing strategies rather than broad DTC advertising in the initial launch phase.
• Adrenaverse Development: Future plans include exploring various routes of administration beyond topical applications, with a focus on patient-centric solutions.

This summary encapsulates the key points from the earnings call, highlighting both the progress and challenges faced by Aquestive Therapeutics as they move forward with their strategic initiatives.